Table 2.

Additional head and neck cancer mortality worldwide considering 40% of reduction of medical care volume during 90-day duration of COVID-19 outbreak, considering a baseline time-to-treatment initiation according to Table 1 and literature review

	New casesa	Deathsa	Increase in medical care during the mitigation period
			50%		20%		15%		10%		5%		No mitigation
			NADc	AFEd	NADc	AFEd	NADc	AFEd	NADc	AFEd	NADc	AFEd	NADc	AFEd
All	705,781	358,144	8,607	2.3	14,559	3.9	17,711	4.7	24,167	6.3	43,496	10.8	47,558	11.7
Continents
Africa	28,127	20,686	675	3.2	1,153	5.3	1,378	6.2	1,885	8.3	3,375	14.0	3,038	12.8
Latin America	48,878	24,239	1,173	4.6	2,004	7.6	2,395	9.0	3,275	11.9	5,914	19.6	5,279	17.9
North America	59,909	13,903	0	–-	0	–-	0	–-	0	–-	0	–-	0	–-
Asia	415,606	231,326	6,650	2.8	11,221	4.6	13,715	5.6	18,702	7.5	33,664	12.7	36,573	13.7
Europe	146,711	66,133	77	0.1	128	0.2	157	0.2	214	0.3	385	0.6	2,347	3.4
Oceania	6,550	1,857	32	1.7	52	2.7	66	3.4	92	4.7	157	7.8	321	14.7
HDIb
Very high	237,509	88,332	53	< 0.1	89	0.1	109	0.1	148	0.2	267	0.3	2,375	2.6
High	154,596	80,342	569	0.7	928	1.1	1,237	1.5	1,701	2.1	2,937	3.5	6,648	7.6
Medium	293,383	174,224	7,041	3.9	12,029	6.5	14,376	7.6	19,657	10.1	35,499	16.9	31,685	15.4
Low	19,994	15,149	480	3.1	820	5.1	980	6.1	1,340	8.1	2,419	13.8	2,159	12.5

^a Source – GLOBOCAN (2018) [11]

^b HDI – Human Development Index

^cNAD – Number of additional deaths

^dAFE—Attributable Fraction in the Exposed Population (%)